论文部分内容阅读
小分子酪氨酸激酶抑制剂伊马替尼是首次研发的针对慢性粒细胞白血病的分子靶向治疗药物,因其临床疗效好、专一性强、不良反应小等优点,成为最有前景的抗肿瘤药物之一。近年来,伊马替尼成为研究的热点,伊马替尼应用于妇科肿瘤的Ⅱ期临床研究也较多。许多妇科肿瘤(如卵巢癌、宫颈癌等)高表达伊马替尼的靶向受体c-kit和血小板衍生生长因子受体,现就其在妇科肿瘤中的研究进展予以综述。
Small molecule tyrosine kinase inhibitor imatinib is the first molecularly targeted therapy for chronic myelogenous leukemia, which is the most promising drug because of its good clinical efficacy, strong specificity and small adverse reactions One of the anti-cancer drugs. In recent years, imatinib has become a hot spot of research, and imatinib is also applied to gynecologic oncology in Phase II clinical research. Many gynecological tumors (such as ovarian cancer, cervical cancer, etc.) high expression of imatinib-targeted receptors c-kit and platelet-derived growth factor receptors, are reviewed in their research progress in gynecologic oncology.